Sector News

Ellen M. Zane rejoins Haemonetics board

January 26, 2018
Life sciences

Haemonetics Corporation announced the election of Ellen M. Zane to its Board of Directors. Zane is a nationally renowned health care leader with more than 30 years of experience in hospitals and healthcare systems.

Zane led the turnaround of Tufts Medical Center and Floating Hospital for Children in Boston, where she retired as President and Chief Executive Officer in 2011 and currently serves as Vice Chair of the Board of Trustees. She returned the organization to financial stability and strengthened its academic relationships and community physician networks to deliver high-quality, cost-efficient and patient-centered care amid rapid change in the healthcare industry.

From 1994 to 2004, Zane was Network President of Partners HealthCare System, Inc., where she developed one of the largest physician networks in the country. Prior to this, she was Chief Executive Officer of Quincy Hospital.

Zane serves on the board of global medical technology leader Boston Scientific Corporation, as well as the boards of Brooks Automation and Fiduciary Trust Company. She is also a former director of PAREXEL International Corporation. Zane previously served on Haemonetics’ Board of Directors from 2012-2016.

“We are pleased to welcome Ellen back to our Board. Her broad expertise in health systems and physician enterprises will bring valuable insights across the company’s growth businesses, especially our Hospital business unit,” said Richard J. Meelia, Chairman of Haemonetics’ Board of Directors. “The Board is committed to renewal in support of Haemonetics’ turnaround. Ellen is the fourth director to join in the past 18 months and will add to the Board’s strong mix of operational and strategic experience as the company transforms to pursue accelerated growth.”

Zane earned a Bachelor of Arts degree from George Washington University and a Master of Arts degree from The Catholic University of America, and holds honorary doctorate degrees from Bentley University, Stonehill College and Curry College. She is on the faculty at Tufts University School of Medicine and The Harvard T. H. Chan School of Public Health.

Source: Haemonetics

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend